Format

Send to

Choose Destination
J Pediatr. 1998 Mar;132(3 Pt 1):543-6.

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.

Author information

1
Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston 77030, USA.

Abstract

Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

PMID:
9544920
DOI:
10.1016/s0022-3476(98)70039-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center